Skip to main content

AVAI BIO, INC.

corporate_fare Company Profile

AVAI BIO, INC.

AVAI·OTC·Life Sciences·CIK 0001740797

AVAI BIO, INC. is a technology company focused on acquiring, creating, and developing advanced technologies that utilize artificial intelligence (AI), and providing information technology consulting services. The company considers itself an expert in AI-based information technology. Key acquisitions include Avant! AI and a Joint Venture and License Agreement with Ainnova Tech Inc. These acquisitions provide resources in full-stack software development, database management, data integration, project management, and cloud services. AVAI BIO, INC. aims to provide AI solutions that transform businesses. Its technology is designed to offer a self-sustained system that prepares data from unlabeled information using Unsupervised Clustering. This data is then analyzed using various proprietary supervised learning techniques to improve data efficiency. Unsupervised learning pre-processes and extracts meaningful features from raw or unlabeled data, preparing them as inputs for the supervised learning model. This process facilitates learning from experience by utilizing unsupervised learning to learn relevant information from many source domains. This knowledge is then evaluated and applied to related or different domains where information might be limited, representing a true learning capability. The company leverages knowledge learned from source domains to improve performance in other domains and for factual discovery and conclusions by learning data. Its unsupervised learning techniques, such as clustering, identify groups or patterns in data to reach conclusions. Subsequently, its supervised learning mechanism creates new datasets, which are used for further domains, improving classification and regression tasks. This feature is described as a true reasoning mechanism. On February 3, 2026, the company changed its corporate name from Avant Technologies, Inc. to Avaí Bio, Inc.

AVAI BIO, INC. (OTC:AVAI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 5 items for AVAI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-30, rated 7/10. Across its 5 most recent items scored 7 or higher, the top rating is 9/10, with 3 rated 8 or above. Recent SEC coverage for AVAI spans 10-Q, 10-K, 8-K.

Recent high-impact activity:

  • Avaí Bio Hits Key Milestone: Klotho-Producing Cells Successfully Encapsulated and Secreting
  • AVAI Bio Posts $552K Quarterly Loss, Cash Rises to $84K, Going Concern Lingers
  • AVAI Bio 10-K Flags Going Concern Doubt, $1.75M Loss, and Material Weaknesses
  • AVAI BIO Terminates AI Healthcare Joint Venture with Ainnova Tech
  • AVAI BIO Reports Substantial Doubt About Going Concern, Ineffective Controls, and Worsening Financials

Financial Snapshot

Fiscal year ended March 31, 2026
Net Income
-$1.75M
Op. Cash Flow
-$1.01M
Operating Income
-$1.75M
Cash & Equivalents
$23.14K
Debt / Equity
0.00×
Shares Outstanding
153.21M sh
Source: 10-K · filed 2026-07-14 · accession 0001740797-26-000017

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 4,409 shares in AVAI as of the September 15, 2026 settlement, a 100.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 61.1% of AVAI volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,409 shares as of September 15, 2026
Change vs prior period▲ 100.0%
Days to cover1.00 at avg daily volume of 260,230
Daily short volume (FINRA facilities)61.1% of 79,989 shares on October 2, 2026
5-day average short volume69.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$0.13 +0.00% today
52-week range · as of 2026-08-13 $0.1104 – $0.80
Market cap
$19.45M
Volume
80K (0.9× avg)
3-mo avg 91.9K
Live data · 2026-10-04 06:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AVAI - Latest Insights

AVAI
Sep 30, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.12586
Real-time Price: $0.130 info
Change: +$0.00414 (+3%) info
Market Cap: $19.448M info
AVAI
Aug 13, 2026, 7:18 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.120
Real-time Price: $0.130 info
Change: +$0.010 (+8%) info
Market Cap: $19.448M info
AVAI
Jul 14, 2026, 3:19 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.1681
Real-time Price: $0.130 info
Change: -$0.0381 (-23%) info
Market Cap: $19.448M info
AVAI
May 08, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.300
Real-time Price: $0.130 info
Change: -$0.170 (-57%) info
Market Cap: $19.448M info
AVAI
Feb 12, 2026, 4:20 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.4021
Real-time Price: $0.130 info
Change: -$0.2721 (-68%) info
Market Cap: $19.448M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets